ライフサイエンスコーパス: experimental allergic encephalomyelitis

1 ovide myelin-specific suppression of ongoing experimental allergic encephalomyelitis.

2 player in MS and its principal animal model, experimental allergic encephalomyelitis.

3 tal immunity that confers resistance against experimental allergic encephalomyelitis.

4 and failed to appropriately resolve induced experimental allergic encephalomyelitis.

5 experimental autoimmune encephalomyelitis or experimental allergic encephalomyelitis.

6 responses was protection of the mice against experimental allergic encephalomyelitis.

7 of neonatal immunity and protection against experimental allergic encephalomyelitis.

8 n the pathogenesis of multiple sclerosis and experimental allergic encephalomyelitis.

9 influence an immune-mediated illness such as experimental allergic encephalomyelitis.

10 d are susceptible to the active induction of experimental allergic encephalomyelitis.

11 oid arthritis, and amyloidosis and mice with experimental allergic encephalomyelitis.

12 ls in a mouse model of MS, chronic relapsing experimental allergic encephalomyelitis.

13 a possible mechanism for the pathogenesis of experimental allergic encephalomyelitis.

14 called into question the Th1-Th2 paradigm in experimental allergic encephalomyelitis.

15 counter myelin-reactive T cells and modulate experimental allergic encephalomyelitis.

16 T-cell-mediated autoimmune diseases such as experimental allergic encephalomyelitis.

17 into effector cells capable of transferring experimental allergic encephalomyelitis.

18 yte glycoprotein (MOG)(35\x{2013}55)-induced experimental allergic encephalomyelitis.

19 occurs and the animals were able to overcome experimental allergic encephalomyelitis.

20 ot substantially interconvert respond during experimental allergic encephalomyelitis.

21 ell as less severe disease manifestations in experimental allergic encephalomyelitis.

22 rogated NaB-mediated protection of Tregs and experimental allergic encephalomyelitis.

23 tal immunity that confers resistance against experimental allergic encephalomyelitis.

24 tent in treating a model autoimmune disease, experimental allergic encephalomyelitis.

25 pression of TIMP1 promotes neuropathology in experimental allergic encephalomyelitis.

26 d present with less severe acute early-phase experimental allergic encephalomyelitis.

27 ted the in vivo effects of tyrphostin B42 in experimental allergic encephalomyelitis, a Th1 cell-medi

28 In their Point of View entitled "Experimental Allergic Encephalomyelitis: A Misleading Mo

29 ed to myelin-specific suppression of ongoing experimental allergic encephalomyelitis (an MS animal mo

30 erties, to treat chronic relapsing-remitting experimental allergic encephalomyelitis, an animal model

31 ulation and ameliorated adoptive transfer of experimental allergic encephalomyelitis, an animal model

32 E4 inhibitors were effective in treatment of experimental allergic encephalomyelitis, an animal model

33 rs, upregulates Tregs and protects mice from experimental allergic encephalomyelitis, an animal model

34 eneficial role for oligodendrocytes (OLG) in experimental allergic encephalomyelitis, an animal model

35 on the clinical and pathological features of experimental allergic encephalomyelitis, an animal model

36 he differentiation of Th1 and Th2 subsets in experimental allergic encephalomyelitis, an autoimmune d

37 Experimental allergic encephalomyelitis, an autoimmune d

38 for 2 weeks ameliorated clinical severity of experimental allergic encephalomyelitis, an effect that

39 r Bphs, a shared autoimmune disease locus in experimental allergic encephalomyelitis and experimental

40 activated effector memory T (T(EM)) cells in experimental allergic encephalomyelitis and in myelin-sp

41 ine that is effective both in suppression of experimental allergic encephalomyelitis and in the treat

42 L-tyrosine, effective both in suppression of experimental allergic encephalomyelitis and in the treat

43 We report that MOBP causes experimental allergic encephalomyelitis and is associate

44 CD5), transgenic mice displayed more severe experimental allergic encephalomyelitis and lupus.

45 r their role in autoimmune processes such as experimental allergic encephalomyelitis and lupus.

46 cules, and suggest that its effectiveness in experimental allergic encephalomyelitis and multiple scl

47 Similar results correlating with experimental allergic encephalomyelitis and orchitis sus

48 7 prone with a concomitant susceptibility to experimental allergic encephalomyelitis and significant

49 This is based on studies in experimental allergic encephalomyelitis and the demonstr

50 other experimental models of demyelination, experimental allergic encephalomyelitis and Theiler's mu

51 +) T(H)17 cells are generated in vivo during experimental allergic encephalomyelitis, and adoptively

52 CNS pathologies such as multiple sclerosis, experimental allergic encephalomyelitis, and Alzheimer's

53 Finally, in the in vivo model of experimental allergic encephalomyelitis, anti-B7.2 mAb t

54 nflammation in a conventional mouse model of experimental allergic encephalomyelitis are dependent up

55 litis virus (TMEV)-induced demyelination and experimental allergic encephalomyelitis are the principa

56 intain T cell tolerance and developed severe experimental allergic encephalomyelitis as well as spont

57 rote, "The most disappointing aspect of EAE [experimental allergic encephalomyelitis] as a potential

58 gated the clinical and pathological signs of experimental allergic encephalomyelitis by causing the d

59 OG Ab specificities in the marmoset model of experimental allergic encephalomyelitis, by means of a c

60 ess autoimmunity in animal models, including experimental allergic encephalomyelitis, collagen and ad

61 3 has key roles in autoimmune destruction in experimental allergic encephalomyelitis, collagen-induce

62 Chronic relapsing experimental allergic encephalomyelitis (CREAE) is an au

63 uppress the autoreactive T cell response and experimental allergic encephalomyelitis development in a

64 nt inhibitor in vivo of CD4+ T-cell-mediated experimental allergic encephalomyelitis disease in the S

65 it is shown that animals with ongoing active experimental allergic encephalomyelitis dramatically red

66 trast, young adult male SJL are resistant to experimental allergic encephalomyelitis due to an APC-de

67 diverse animal models of autoimmune disease, experimental allergic encephalomyelitis (EAE) and experi

68 ferential susceptibility to actively induced experimental allergic encephalomyelitis (EAE) and experi

69 Experimental allergic encephalomyelitis (EAE) and its hu

70 Experimental allergic encephalomyelitis (EAE) and multip

71 Experimental allergic encephalomyelitis (EAE) and Theile

72 +) T cells in two autoimmune disease models, experimental allergic encephalomyelitis (EAE) and type 1

73 the neuroantigen-specific effector cells in experimental allergic encephalomyelitis (EAE) are a cont

74 h the development of neurological disease in experimental allergic encephalomyelitis (EAE) but not du

75 ene (Esr1(-/-)) develop less severe clinical experimental allergic encephalomyelitis (EAE) compared t

76 receptor-modified CTL ameliorated or blocked experimental allergic encephalomyelitis (EAE) disease me

77 an C-reactive protein (CRP) protects against experimental allergic encephalomyelitis (EAE) in C57BL/6

78 mined by investigation of the development of experimental allergic encephalomyelitis (EAE) in CD40L-d

79 n oligodendrocyte glycoprotein (MOG)-induced experimental allergic encephalomyelitis (EAE) in marmose

80 g major oligodendrocyte glycoprotein-induced experimental allergic encephalomyelitis (EAE) in normal

81 the expression and development of relapsing experimental allergic encephalomyelitis (EAE) in SJL mic

82 he development of fatal CD4+ T cell-mediated experimental allergic encephalomyelitis (EAE) in suscept

83 s evaluated using the demyelinating model of experimental allergic encephalomyelitis (EAE) in the com

84 In this study, we used uric acid to treat experimental allergic encephalomyelitis (EAE) in the PLS

85 ls or CD4+CD25- RMTCs, prevented and treated experimental allergic encephalomyelitis (EAE) induced wi

86 Experimental allergic encephalomyelitis (EAE) is a CD4(+

87 Experimental allergic encephalomyelitis (EAE) is a CNS a

88 hesis is that MS is immune mediated and that experimental allergic encephalomyelitis (EAE) is a suita

89 Experimental allergic encephalomyelitis (EAE) is a T cel

90 Experimental allergic encephalomyelitis (EAE) is a T cel

91 Experimental allergic encephalomyelitis (EAE) is a Th1 c

92 Experimental allergic encephalomyelitis (EAE) is a Th1-m

93 Murine experimental allergic encephalomyelitis (EAE) is a usefu

94 Experimental allergic encephalomyelitis (EAE) is a widel

95 Experimental allergic encephalomyelitis (EAE) is an anim

96 n oligodendrocyte glycoprotein (MOG) induced experimental allergic encephalomyelitis (EAE) is an anim

97 Experimental allergic encephalomyelitis (EAE) is an auto

98 Experimental allergic encephalomyelitis (EAE) is an auto

99 Experimental allergic encephalomyelitis (EAE) is an infl

100 Experimental allergic encephalomyelitis (EAE) is an infl

101 Experimental allergic encephalomyelitis (EAE) is induced

102 rphic, demyelinating disease of the CNS, and experimental allergic encephalomyelitis (EAE) is its pri

103 Experimental allergic encephalomyelitis (EAE) is the ani

104 Experimental allergic encephalomyelitis (EAE) is the ani

105 Experimental allergic encephalomyelitis (EAE) is the pri

106 Experimental allergic encephalomyelitis (EAE) is the pri

107 amma delta T cells in multiple sclerosis and experimental allergic encephalomyelitis (EAE) lesions bu

108 apeutically, Ag-specifically treating murine experimental allergic encephalomyelitis (EAE) mediated b

109 multiple sclerosis and in its animal model, experimental allergic encephalomyelitis (EAE) remain equ

110 organ-specific autoimmune diseases, such as experimental allergic encephalomyelitis (EAE) the princi

111 n (Ag) presentation and T cell activation in experimental allergic encephalomyelitis (EAE) was evalua

112 Monophasic experimental allergic encephalomyelitis (EAE) was induce

113 also important in a second autoimmune model, experimental allergic encephalomyelitis (EAE) was induce

114 transduced cloned Th1 cells, the severity of experimental allergic encephalomyelitis (EAE) was slight

115 Gender-related differences in experimental allergic encephalomyelitis (EAE) were exami

116 A.SW mice develop PP or SP-experimental allergic encephalomyelitis (EAE) with large

117 Experimental allergic encephalomyelitis (EAE), a demyeli

118 ganization of sodium channels along axons in experimental allergic encephalomyelitis (EAE), a model o

119 Experimental allergic encephalomyelitis (EAE), a model o

120 se severity in C57BL/6 (B6) strain-dependent experimental allergic encephalomyelitis (EAE), a model o

121 the development of Ag-specific Th1 cells in experimental allergic encephalomyelitis (EAE), a model o

122 )) exhibit significantly reduced severity of experimental allergic encephalomyelitis (EAE), a murine

123 uption of the lyn gene on the development of experimental allergic encephalomyelitis (EAE), a well-es

124 protocol details a method to actively induce experimental allergic encephalomyelitis (EAE), a widely

125 ARgamma agonists reduce clinical severity of experimental allergic encephalomyelitis (EAE), an animal

126 he disease process in adoptively transferred experimental allergic encephalomyelitis (EAE), an animal

127 , the administration of UA is therapeutic in experimental allergic encephalomyelitis (EAE), an animal

128 calpain expression in Lewis rats with acute experimental allergic encephalomyelitis (EAE), an animal

129 examined in spinal cords of Lewis rats with experimental allergic encephalomyelitis (EAE), an animal

130 ession was examined in Lewis rats with acute experimental allergic encephalomyelitis (EAE), an animal

131 We examined how experimental allergic encephalomyelitis (EAE), an animal

132 se processes would be expected to exacerbate experimental allergic encephalomyelitis (EAE), an animal

133 position of white matter from marmosets with experimental allergic encephalomyelitis (EAE), an animal

134 9) are bioactive cytokines and their role in experimental allergic encephalomyelitis (EAE), an animal

135 proaches have been developed that ameliorate experimental allergic encephalomyelitis (EAE), an animal

136 he disease process of adoptively transferred experimental allergic encephalomyelitis (EAE), an animal

137 n this study that Tkip protects mice against experimental allergic encephalomyelitis (EAE), an animal

138 Experimental allergic encephalomyelitis (EAE), an autoim

139 c contributor to multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE), but multi

140 s rats, on recovery from monophasic clinical experimental allergic encephalomyelitis (EAE), can be in

141 nted and treated a model autoimmune disease, experimental allergic encephalomyelitis (EAE), even afte

142 s system (CNS) of mice with actively induced experimental allergic encephalomyelitis (EAE), that expr

143 driven autoimmune disease, recent studies in experimental allergic encephalomyelitis (EAE), the anima

144 and a known autoantigen capable of inducing experimental allergic encephalomyelitis (EAE), the anima

145 not understood, and Ab inhibition studies in experimental allergic encephalomyelitis (EAE), the anima

146 Histamine (HA) is a key regulator of experimental allergic encephalomyelitis (EAE), the autoi

147 rosis patients and during the development of experimental allergic encephalomyelitis (EAE), the contr

148 y of (B10.S x SJL/J) F(2) intercross mice to experimental allergic encephalomyelitis (EAE), the forem

149 Experimental allergic encephalomyelitis (EAE), the princ

150 Experimental allergic encephalomyelitis (EAE), the princ

151 oth chronic and relapsing-remitting forms of experimental allergic encephalomyelitis (EAE), the princ

152 iated central component in susceptibility to experimental allergic encephalomyelitis (EAE), the princ

153 Susceptibility to experimental allergic encephalomyelitis (EAE), the princ

154 In this study, we used a murine model of MS, experimental allergic encephalomyelitis (EAE), to assess

155 ) transfer system was devised and applied to experimental allergic encephalomyelitis (EAE), to evalua

156 odendrocyte glycoprotein MOG(35-55)- induced experimental allergic encephalomyelitis (EAE), we assess

157 test this system for tolerance induction in experimental allergic encephalomyelitis (EAE), we create

158 ion in the optic nerves of mice induced with experimental allergic encephalomyelitis (EAE), with a fo

159 nical symptoms and inflammatory responses in experimental allergic encephalomyelitis (EAE)-induced mi

160 in basic protein (MBP)-specific T cells from experimental allergic encephalomyelitis (EAE)-susceptibl

161 sodium channels along demyelinated axons in experimental allergic encephalomyelitis (EAE).

162 st both the induced and spontaneous forms of experimental allergic encephalomyelitis (EAE).

163 combination with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE).

164 protein (MOG) peptide 35-55 in CFA to induce experimental allergic encephalomyelitis (EAE).

165 tion of leukocytes into the CNS of mice with experimental allergic encephalomyelitis (EAE).

166 n the pathogenesis of multiple sclerosis and experimental allergic encephalomyelitis (EAE).

167 ral different autoimmune diseases, including experimental allergic encephalomyelitis (EAE).

168 t to suppress both clinical and histological experimental allergic encephalomyelitis (EAE).

169 and Fas ligand (FasL) in the pathogenesis of experimental allergic encephalomyelitis (EAE).

170 experimental autoimmune diseases, including experimental allergic encephalomyelitis (EAE).

171 analyzed its effects in an autoimmune model, experimental allergic encephalomyelitis (EAE).

172 s tested in the optic nerves of animals with experimental allergic encephalomyelitis (EAE).

173 mmatory diseases multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE).

174 T cells responsible for the pathogenesis of experimental allergic encephalomyelitis (EAE).

175 the role of this T cell surface molecule in experimental allergic encephalomyelitis (EAE).

176 ed-type hypersensitivity (DTH) responses and experimental allergic encephalomyelitis (EAE).

177 a spectrum of susceptibility to induction of experimental allergic encephalomyelitis (EAE).

178 s in white matter of the CNS and symptoms of experimental allergic encephalomyelitis (EAE).

179 PARs) agonists ameliorate MS-like disease in experimental allergic encephalomyelitis (EAE).

180 with the murine model of multiple sclerosis, experimental allergic encephalomyelitis (EAE).

181 are important in both multiple sclerosis and experimental allergic encephalomyelitis (EAE).

182 genic functions and proved effective against experimental allergic encephalomyelitis (EAE).

183 information is also not available for murine experimental allergic encephalomyelitis (EAE); the low n

184 from "normal" (healthy) and "disease-like" [experimental allergic encephalomyelitis (EAE)] animals.

185 filtrating the central nervous system during experimental allergic encephalomyelitis express the C5aR

186 the composition of myelin from animals with experimental allergic encephalomyelitis had slightly low

187 are relatively resistant to the induction of experimental allergic encephalomyelitis, implying the in

188 n of autoimmunity, particularly diabetes and experimental allergic encephalomyelitis in animal models

189 allin-specific T cells to induce symptoms of experimental allergic encephalomyelitis in animal models

190 NTB-A-Fc delays the onset of antigen-induced experimental allergic encephalomyelitis in myelin basic

191 rogression of adjuvant-induced arthritis and experimental allergic encephalomyelitis in rodents.

192 After the induction of experimental allergic encephalomyelitis in SJL mice with

193 induced isotype switching and attenuation of experimental allergic encephalomyelitis indicate that NT

194 e also less susceptible to acute early-phase experimental allergic encephalomyelitis indicating that

195 MBP-IgG leads to the amelioration of ongoing experimental allergic encephalomyelitis induced by the t

196 tides silence aggressive T cells and reverse experimental allergic encephalomyelitis induced with fre

197 readily accessible autoantigens, we studied experimental allergic encephalomyelitis, induced by myel

198 production of protective cytokines prior to experimental allergic encephalomyelitis induction and de

199 ted epitopes and promoted protection against experimental allergic encephalomyelitis involving divers

200 Experimental allergic encephalomyelitis is a prototypic

201 To more precisely map these TMEV and experimental allergic encephalomyelitis loci relative to

202 BX 471 effectively reduces disease in a rat experimental allergic encephalomyelitis model of multipl

203 ers of nitric oxide and peroxynitrite in the experimental allergic encephalomyelitis model.

204 ited the course of neural inflammation in an experimental allergic encephalomyelitis model.

205 ection from autoimmune encephalopathy in the experimental allergic encephalomyelitis model.

206 myelin oligodendroglial glycoprotein-induced experimental allergic encephalomyelitis (MOG-EAE).

207 eutic benefit vs risk of immune deviation in experimental allergic encephalomyelitis of SJL mice indu

208 nduced type 2 T cell immunity, IgG1 Abs, and experimental allergic encephalomyelitis protection, and

209 MOBP-induced experimental allergic encephalomyelitis shows a severe c

210 In an adoptive transfer model of experimental allergic encephalomyelitis, stimulation of

211 H(1)R(S) allele in T cells fully complements experimental allergic encephalomyelitis susceptibility a

212 or the HR (13R(-/-)) are more susceptible to experimental allergic encephalomyelitis than mice suffic

213 hat lpr and gld mice are less susceptible to experimental allergic encephalomyelitis than their wild-

214 mic Ag administration in a marmoset model of experimental allergic encephalomyelitis that closely res

215 ons, and also plays a key regulatory role in experimental allergic encephalomyelitis, the autoimmune

216 cal settings, plays a key regulatory role in experimental allergic encephalomyelitis, the autoimmune

217 um-activated neutral proteinase (calpain) in experimental allergic encephalomyelitis, the correspondi

218 There are a variety of forms of experimental allergic encephalomyelitis, the most common

219 In acute and relapsing-remitting experimental allergic encephalomyelitis, the neutrophil

220 rsensitivity to histamine, a subphenotype of experimental allergic encephalomyelitis, the principal a

221 orylated neurofilament on thickened axons in experimental allergic encephalomyelitis tissue.

222 in the spleens or CNS of wild-type mice with experimental allergic encephalomyelitis to determine the

223 ases of disease severity in animal models of experimental allergic encephalomyelitis, type I diabetes

224 to clinical or histological manifestation of experimental allergic encephalomyelitis unless pertussis

225 /-)) mice were unable to resist or alleviate experimental allergic encephalomyelitis when treated wit